NC
Nantahala Capital Management, LLC
13F filer · CIK 0001472322Reported Aug 19, 2026
Net buyer this quarter
13F portfolio value$6.02BU.S. long equity reported on 13F
Positions13120 new · 18 closed
Net flow last quarter+$1.44BBuys minus sells
Top 10 positions weight15.1%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 19, 2026131 positions | |||||
| $155M | 2.58% | 6.04% | +79.6% | Q2 2014 | |
| $113M | 1.88% | Not reported | +96.0% | Q3 2022 | |
| $108M | 1.80% | 2.65% | +36.5% | Q4 2022 | |
| $86M | 1.43% | 6.79% | +90.0% | Q3 2023 | |
| $85.1M | 1.41% | 8.31% | +100.0% | Q2 2024 | |
| $78.5M | 1.30% | 1.42% | +59.5% | Q1 2023 | |
| $77.8M | 1.29% | 16.97% | +75.7% | Q3 2023 | |
| $68.8M | 1.14% | 7.04% | +201.6% | Q3 2021 | |
| $68.3M | 1.14% | 7.34% | +100.0% | Q3 2025 | |
| $66.7M | 1.11% | 6.95% | +22.3% | Q4 2024 | |
| $63.5M | 1.05% | 17.95% | +104.9% | Q4 2022 | |
| $60.4M | 1.00% | Not reported | -14.9% | Q1 2020 | |
| $57.6M | 0.96% | 2.25% | -19.4% | Q3 2018 | |
| $57.6M | 0.96% | 97.52% | +100.0% | Q3 2023 | |
| $54.7M | 0.91% | 18.13% | +124.1% | Q2 2025 | |
| $53.9M | 0.90% | 12.84% | +95.9% | Q3 2024 | |
| $52.5M | 0.87% | 2.40% | +155.3% | Q4 2020 | |
| $51.6M | 0.86% | 6.06% | +42.6% | Q3 2023 | |
| $47.9M | 0.80% | 9.73% | +80.6% | Q3 2024 | |
| $47.1M | 0.78% | 15.31% | +100.0% | Q4 2020 | |
| $45.6M | 0.76% | 18.63% | +103.7% | Q2 2023 | |
| $44.4M | 0.74% | 6.25% | +76.1% | Q4 2024 | |
| $44.3M | 0.74% | 1.86% | +83.3% | Q1 2024 | |
| $43.6M | 0.72% | 298.67% | +100.0% | Q2 2022 | |
| $42M | 0.70% | 1.31% | +284.4% | Q4 2016 | |
| $41.9M | 0.70% | 5.70% | +178.7% | Q4 2021 | |
| $40.7M | 0.68% | 9.18% | +161.4% | Q1 2026 | |
| $40.1M | 0.67% | 14.35% | +259.0% | Q4 2022 | |
| $39.8M | 0.66% | 8.65% | +107.0% | Q2 2024 | |
| $39.5M | 0.66% | 2.09% | New | Q2 2026 | |
| $38.9M | 0.65% | Not reported | +56.5% | Q4 2025 | |
| $38M | 0.63% | 1.49% | +91.3% | Q4 2025 | |
| $36.7M | 0.61% | 6.54% | +180.7% | Q4 2022 | |
| $35.6M | 0.59% | 0.34% | +94.9% | Q4 2023 | |
| $34.6M | 0.57% | 8.78% | +100.0% | Q4 2025 | |
| $31.6M | 0.52% | 1.53% | +100.0% | Q4 2025 | |
| $31.3M | 0.52% | 0.59% | -19.9% | Q3 2021 | |
| $31.3M | 0.52% | 3.81% | +117.8% | Q3 2025 | |
| $31.1M | 0.52% | 3.10% | New | Q2 2026 | |
| $30.2M | 0.50% | 14.23% | +107.4% | Q2 2020 | |
| $29.6M | 0.49% | 1.90% | +25.5% | Q1 2024 | |
| $29.4M | 0.49% | 15.53% | +90.1% | Q4 2024 | |
| $29.2M | 0.49% | 2.61% | +100.0% | Q2 2025 | |
| $29.2M | 0.48% | 2.12% | +63.9% | Q1 2025 | |
| $29.1M | 0.48% | 558000.00% | Not reported | Q1 2020 | |
| $27.4M | 0.46% | 7.92% | +100.0% | Q2 2024 | |
| $27.1M | 0.45% | 2.14% | +100.0% | Q2 2025 | |
| $26.7M | 0.44% | 5.02% | +112.2% | Q1 2016 | |
| $26.6M | 0.44% | Not reported | +100.0% | Q1 2026 | |
| $26.4M | 0.44% | 19.34% | +340.4% | Q4 2022 | |
| Q1 2026Reported May 15, 2026129 positions | |||||
| $74.2M | 2.73% | 3.30% | +28.8% | Q2 2014 | |
| $59.2M | 2.18% | 1.88% | -3.1% | Q4 2022 | |
| STSLNOSoleno Therapeutics Inc | $58.4M | 2.15% | 3.37% | +32.7% | Q4 2019 |
| $55.9M | 2.06% | Not reported | +1.2% | Q3 2022 | |
| $51.5M | 1.90% | Not reported | +102.3% | Q1 2020 | |
| $47.3M | 1.74% | 2.83% | -15.7% | Q3 2018 | |
| $40.1M | 1.48% | 3.58% | Not reported | Q3 2023 | |
| $38.2M | 1.40% | 48.83% | Not reported | Q3 2023 | |
| $35.7M | 1.31% | 6.57% | +30.8% | Q3 2024 | |
| $35.4M | 1.30% | 0.90% | +16.2% | Q1 2023 | |
| $30.7M | 1.13% | 5.69% | +118.5% | Q4 2024 | |
| $29M | 1.07% | 4.30% | Not reported | Q2 2024 | |
| $26.2M | 0.96% | 9.69% | +9.6% | Q3 2023 | |
| $26.2M | 0.96% | 0.87% | -65.0% | Q3 2021 | |
| $26M | 0.96% | 3.67% | +56.0% | Q3 2025 | |
| $24.5M | 0.90% | 3.56% | -32.0% | Q4 2024 | |
| $24.3M | 0.89% | 1.09% | +690.5% | Q1 2024 | |
| $23.5M | 0.87% | 4.27% | +42.3% | Q3 2023 | |
| $23.4M | 0.86% | 4.58% | -29.0% | Q4 2022 | |
| $23.3M | 0.86% | 9.26% | +6.7% | Q2 2023 | |
| $23.1M | 0.85% | 149.33% | Not reported | Q2 2022 | |
| $22.5M | 0.83% | 8.82% | +1.0% | Q4 2022 | |
| $22.3M | 0.82% | Not reported | +207.9% | Q4 2025 | |
| $21M | 0.77% | 4.40% | +2.2% | Q4 2022 | |
| $21M | 0.77% | 5.37% | +2.8% | Q3 2024 | |
| $19.9M | 0.73% | 1.31% | +53.5% | Q1 2025 | |
| $19.6M | 0.72% | 0.94% | +8.1% | Q4 2020 | |
| $19M | 0.70% | 4.08% | +675.7% | Q2 2024 | |
| $18.9M | 0.70% | 0.78% | +46.5% | Q4 2025 | |
| $18.4M | 0.68% | 5.01% | Not reported | Q3 2021 | |
| $17.8M | 0.65% | 7.65% | Not reported | Q4 2020 | |
| $17.7M | 0.65% | 2.37% | -11.1% | Q1 2016 | |
| $16.7M | 0.62% | 1.75% | +24.4% | Q3 2025 | |
| $15.3M | 0.56% | 4.19% | +38.5% | Q2 2024 | |
| $15.3M | 0.56% | 0.17% | -10.4% | Q4 2023 | |
| $15.1M | 0.56% | 0.50% | +68.6% | Q4 2025 | |
| $15M | 0.55% | 6.89% | +277.5% | Q2 2020 | |
| $14.9M | 0.55% | 8.10% | +78.1% | Q2 2025 | |
| $14.4M | 0.53% | 1.35% | +25.0% | Q2 2025 | |
| $14.2M | 0.52% | 3.30% | Not reported | Q4 2021 | |
| $14.2M | 0.52% | 4.39% | +38.5% | Q4 2025 | |
| $13.9M | 0.51% | 0.17% | New | Q1 2026 | |
| $13.4M | 0.49% | 2.28% | +40.6% | Q4 2022 | |
| AHASRTAssertio Holdings, Inc. | $13.2M | 0.49% | 10.74% | +17.9% | Q3 2023 |
| $13M | 0.48% | 1.07% | +49.9% | Q2 2025 | |
| $12.9M | 0.47% | 3.51% | New | Q1 2026 | |
| $12.7M | 0.47% | Not reported | New | Q1 2026 | |
| $12.7M | 0.47% | 8.22% | -13.4% | Q4 2024 | |
| $11.3M | 0.42% | 1.51% | +39.2% | Q1 2024 | |
| $11.3M | 0.41% | 1.33% | New | Q1 2026 | |
| Q4 2025Reported Feb 13, 2026131 positions | |||||
| $72.4M | 2.39% | 2.53% | +25.7% | Q2 2014 | |
| $72M | 2.38% | 3.37% | -50.0% | Q3 2018 | |
| $69.9M | 2.31% | 1.88% | -6.4% | Q4 2022 | |
| STSLNOSoleno Therapeutics Inc | $60.8M | 2.01% | 2.51% | +52.1% | Q4 2019 |
| $53.6M | 1.77% | 48.84% | Not reported | Q3 2023 | |
| $48.6M | 1.61% | 6.45% | -8.1% | Q4 2022 | |
| $45M | 1.49% | Not reported | +4.1% | Q3 2022 | |
| $44.3M | 1.46% | 3.59% | -16.3% | Q3 2023 | |
| $38.7M | 1.28% | 8.95% | +1.6% | Q3 2023 | |
| $37.4M | 1.24% | 5.24% | +200.3% | Q4 2024 | |
| $36.5M | 1.21% | Not reported | +60.4% | Q1 2020 | |
| $31.7M | 1.05% | 5.05% | Not reported | Q3 2024 | |
| $31.7M | 1.05% | 2.63% | +97.4% | Q3 2021 | |
| $30.8M | 1.02% | 0.78% | -42.1% | Q1 2023 | |
| EEBEventbrite, Inc. | $30.5M | 1.01% | 6.83% | +0.3% | Q2 2024 |
| $26.2M | 0.86% | 9.02% | +8.7% | Q4 2022 | |
| RTRAPTRAPT Therapeutics, Inc. | $25.5M | 0.84% | 2.72% | +21.0% | Q4 2024 |
| $23.9M | 0.79% | 7.07% | -10.6% | Q3 2025 | |
| $22.4M | 0.74% | 6.67% | Not reported | Q3 2021 | |
| $20.7M | 0.68% | 0.20% | -72.5% | Q4 2023 | |
| $19.9M | 0.66% | 4.35% | Not reported | Q2 2024 | |
| $19.6M | 0.65% | 0.17% | -25.0% | Q3 2025 | |
| $19.3M | 0.64% | 4.35% | +141.6% | Q4 2022 | |
| $19M | 0.63% | 9.27% | +35.4% | Q2 2023 | |
| $18.4M | 0.61% | 5.22% | +11.3% | Q3 2024 | |
| $18.1M | 0.60% | 149.33% | Not reported | Q2 2022 | |
| $17.6M | 0.58% | 0.88% | -52.1% | Q4 2020 | |
| $17.1M | 0.57% | 7.65% | Not reported | Q4 2020 | |
| $16.7M | 0.55% | 1.12% | -30.6% | Q4 2016 | |
| $16.4M | 0.54% | 4.58% | +44.3% | Q2 2025 | |
| $16.4M | 0.54% | 1.63% | +64.8% | Q4 2022 | |
| $16.3M | 0.54% | 7.77% | Not reported | Q2 2016 | |
| $15.9M | 0.52% | 3.12% | -10.1% | Q3 2023 | |
| $15.5M | 0.51% | 0.87% | Not reported | Q3 2023 | |
| $15M | 0.50% | 2.67% | Not reported | Q3 2025 | |
| $14.5M | 0.48% | 4.14% | +1.5% | Q2 2025 | |
| ATATXSAstria Therapeutics, Inc. | $14M | 0.46% | 1.87% | Not reported | Q2 2024 |
| $14M | 0.46% | 3.03% | +23.9% | Q2 2024 | |
| $13.9M | 0.46% | 9.51% | +19.1% | Q4 2024 | |
| $13.4M | 0.44% | 0.91% | -16.8% | Q4 2024 | |
| $13.4M | 0.44% | 1.03% | Not reported | Q2 2025 | |
| $13.3M | 0.44% | Not reported | +0.2% | Q3 2018 | |
| $13M | 0.43% | 21.00% | Not reported | Q4 2024 | |
| $12.6M | 0.42% | 6.09% | +31.9% | Q4 2024 | |
| $11.9M | 0.39% | 1.41% | Not reported | Q3 2025 | |
| $11.5M | 0.38% | 3.33% | Not reported | Q4 2021 | |
| $11.5M | 0.38% | 3.20% | New | Q4 2025 | |
| $11.4M | 0.38% | 0.85% | -6.4% | Q1 2025 | |
| $10.6M | 0.35% | 2.69% | +252.6% | Q1 2016 | |
| $10.6M | 0.35% | 0.64% | New | Q4 2025 | |
| Q3 2025Reported Nov 14, 2025131 positions | |||||
| $80.9M | 2.81% | 6.79% | +11.2% | Q3 2018 | |
| $69.7M | 2.42% | 1.93% | -16.2% | Q4 2022 | |
| $63.8M | 2.22% | 1.91% | -12.0% | Q2 2014 | |
| $58.8M | 2.04% | 1.62% | -50.9% | Q4 2016 | |
| STSLNOSoleno Therapeutics Inc | $58.4M | 2.03% | 1.61% | -13.7% | Q4 2019 |
| $47.3M | 1.64% | 0.88% | -62.4% | Q4 2023 | |
| $44.4M | 1.54% | 48.85% | Not reported | Q3 2023 | |
| $43M | 1.49% | 8.63% | +8.9% | Q4 2022 | |
| $42.3M | 1.47% | 1.35% | -3.3% | Q1 2023 | |
| $38.9M | 1.35% | Not reported | +10.0% | Q3 2022 | |
| $35.2M | 1.22% | 8.84% | +36.4% | Q3 2023 | |
| $33.3M | 1.16% | Not reported | +13.2% | Q1 2020 | |
| $32.6M | 1.13% | 1.85% | -12.2% | Q4 2020 | |
| $31.3M | 1.09% | 5.08% | +5.4% | Q3 2023 | |
| $25.6M | 0.89% | 4.39% | Not reported | Q2 2024 | |
| $24.1M | 0.84% | 8.71% | +4.5% | Q4 2022 | |
| $23.8M | 0.83% | 2.13% | -41.0% | Q1 2024 | |
| $21.6M | 0.75% | 1.08% | -9.0% | Q2 2023 | |
| $19.5M | 0.68% | 3.04% | -23.9% | Q2 2020 | |
| $19.3M | 0.67% | 9.18% | New | Q3 2025 | |
| $19.1M | 0.66% | 4.20% | -12.4% | Q4 2024 | |
| $19M | 0.66% | 0.82% | Not reported | Q4 2022 | |
| $18.8M | 0.65% | 7.79% | Not reported | Q2 2016 | |
| $18.8M | 0.65% | 3.51% | +34.0% | Q3 2023 | |
| $18.4M | 0.64% | 4.69% | -3.5% | Q3 2024 | |
| $18.1M | 0.63% | 7.65% | Not reported | Q4 2020 | |
| $17.7M | 0.61% | 1.74% | Not reported | Q4 2024 | |
| EEBEventbrite, Inc. | $17.2M | 0.60% | 7.07% | +7.1% | Q2 2024 |
| $17.2M | 0.60% | 0.22% | New | Q3 2025 | |
| RTRAPTRAPT Therapeutics, Inc. | $16.1M | 0.56% | 3.77% | -34.5% | Q4 2024 |
| $15.7M | 0.55% | 6.93% | +24.1% | Q3 2021 | |
| $15.7M | 0.54% | 2.26% | Not reported | Q4 2024 | |
| $15.5M | 0.54% | Not reported | +68.4% | Q3 2018 | |
| $15.2M | 0.53% | 1.62% | -47.4% | Q3 2021 | |
| $14.8M | 0.51% | 0.88% | Not reported | Q3 2023 | |
| $14.4M | 0.50% | 149.33% | Not reported | Q2 2022 | |
| $13.1M | 0.45% | 3.36% | Not reported | Q4 2021 | |
| $12.9M | 0.45% | 1.54% | +34.1% | Q1 2025 | |
| $12.7M | 0.44% | 0.85% | -68.1% | Q2 2023 | |
| $12.4M | 0.43% | 1.41% | New | Q3 2025 | |
| $11.9M | 0.41% | 0.72% | Not reported | Q2 2025 | |
| $11.8M | 0.41% | 3.19% | Not reported | Q2 2024 | |
| $11.4M | 0.40% | 1.94% | -56.2% | Q2 2024 | |
| $11.2M | 0.39% | 1.10% | Not reported | Q4 2024 | |
| $10.7M | 0.37% | 2.67% | New | Q3 2025 | |
| $10.5M | 0.36% | 2.18% | -0.2% | Q1 2025 | |
| $10.4M | 0.36% | 1.03% | Not reported | Q2 2025 | |
| $10.3M | 0.36% | 0.20% | +118.7% | Q1 2023 | |
| $10.2M | 0.36% | 0.99% | Not reported | Q4 2022 | |
| $9.91M | 0.34% | 1.80% | -58.6% | Q3 2024 | |
Premium opens every quarter this fund has filed